(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Quarter results tomorrow
(bmo 2024-04-29)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands...
Stats | |
---|---|
今日成交量 | 70 820.00 |
平均成交量 | 92 922.00 |
市值 | 134.31B |
EPS | €0 ( 2024-01-30 ) |
下一个收益日期 | ( €0 ) 2024-04-29 |
Last Dividend | €0.410 ( 2023-07-27 ) |
Next Dividend | €0 ( N/A ) |
P/E | 69.96 |
ATR14 | €0.0470 (0.20%) |
音量 相关性
Pfizer Inc 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Pfizer Inc 相关性 - 货币/商品
Pfizer Inc 财务报表
Annual | 2023 |
营收: | €58.50B |
毛利润: | €33.54B (57.34 %) |
EPS: | €0.380 |
FY | 2023 |
营收: | €58.50B |
毛利润: | €33.54B (57.34 %) |
EPS: | €0.380 |
FY | 2022 |
营收: | €100.33B |
毛利润: | €65.99B (65.77 %) |
EPS: | €5.63 |
FY | 2021 |
营收: | €81.29B |
毛利润: | €50.47B (62.08 %) |
EPS: | €3.95 |
Financial Reports:
No articles found.
Pfizer Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0.400 (N/A) |
€0.400 (N/A) |
€0.410 (N/A) |
€0.410 (N/A) |
€0.410 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.325 | 2008-01-11 |
Last Dividend | €0.410 | 2023-07-27 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 68 | -- |
Total Paid Out | €20.64 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.7 | -- |
Div. Sustainability Score | 6.07 | |
Div.Growth Potential Score | 4.08 | |
Div. Directional Score | 5.07 | -- |
Year | Amount | Yield |
---|
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
NWT.DE | Ex Dividend Knight | 2023-08-03 | Quarterly | 0 | 0.00% | |
AISF.F | Ex Dividend Knight | 2023-08-18 | Semi-Annually | 0 | 0.00% | |
GUI.DE | Ex Dividend Knight | 2023-08-24 | Semi-Annually | 0 | 0.00% | |
QCI.DE | Ex Dividend Knight | 2023-08-30 | Quarterly | 0 | 0.00% | |
BNR.DE | Ex Dividend Knight | 2023-06-16 | Annually | 0 | 0.00% | |
INS.DE | Ex Dividend Junior | 2023-06-15 | Annually | 0 | 0.00% | |
SY1.DE | Ex Dividend Knight | 2023-05-11 | Annually | 0 | 0.00% | |
DAM.DE | Ex Dividend Junior | 2023-05-10 | Annually | 0 | 0.00% | |
LXS.DE | Ex Dividend Junior | 2023-05-25 | Annually | 0 | 0.00% | |
2X0.DE | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0367 | 1.500 | 9.27 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00947 | 1.200 | 9.68 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0222 | 1.500 | -0.864 | -1.296 | [0.1 - 1] |
payoutRatioTTM | 4.31 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 0.907 | 0.800 | -0.467 | -0.373 | [1 - 3] |
quickRatioTTM | 0.583 | 0.800 | -1.279 | -1.023 | [0.8 - 2.5] |
cashRatioTTM | 0.0597 | 1.500 | -0.779 | -1.169 | [0.2 - 2] |
debtRatioTTM | 0.313 | -1.500 | 4.79 | -7.18 | [0 - 0.6] |
interestCoverageTTM | 0.551 | 1.000 | -0.907 | -0.907 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.555 | 2.00 | 9.48 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.856 | 2.00 | 9.57 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.796 | -1.500 | 6.82 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.479 | 1.000 | 5.36 | 5.36 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0208 | 1.000 | -1.584 | -1.584 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.123 | 1.000 | -0.429 | -0.429 | [0.2 - 2] |
assetTurnoverTTM | 0.258 | 0.800 | -1.612 | -1.289 | [0.5 - 2] |
Total Score | 6.07 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 66.39 | 1.000 | 3.39 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0222 | 2.50 | -0.555 | -1.296 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.856 | 2.00 | 9.71 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 6.48 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.555 | 2.00 | 9.48 | 10.00 | [0 - 30] |
payoutRatioTTM | 4.31 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | -2.39 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.149 | 1.000 | 8.78 | 0 | [0.1 - 0.5] |
Total Score | 4.08 |
Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。